Seismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shock

Seismic Pharmaceuticals has enrolled the first patient in its global Phase 3 trial of istaroxime, a drug designed to treat cardiogenic shock, a condition with high mortality and no approved therapies. The trial targets 600 patients across the US, Europe, China, and South America, building on promising Phase 2 results showing improved cardiac output and reduced arrhythmia risk.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.